Nuclear receptor-interacting protein 1 (NRIP1)

Nuclear receptor-interacting protein 1 (NRIP1), also known as RIP140, is a nuclear protein that functions as a key transcriptional coregulator and predominantly as a corepressor for a variety of nuclear hormone receptors, including estrogen, retinoid, androgen, glucocorticoid, and thyroid hormone receptors[1][2][4]. The NRIP1 protein contains several functional domains (notably LxxLL motifs) allowing interaction with nuclear receptors and other transcription factors, and it is regulated through multiple post-translational modifications such as SUMOylation[4]. NRIP1's central function is to modulate hormone-regulated gene expression in diverse biological contexts by recruiting chromatin-remodeling enzymes like histone deacetylases and carboxyl-terminal-binding proteins, thereby repressing transcriptional activation and fine-tuning gene expression[2][4][5]. NRIP1 plays crucial roles in energy metabolism (regulation of lipid and glucose metabolism, inhibition of energy-dissipating genes in adipose tissue), female fertility, circadian clock function, immune response regulation, and cell cycle control[1][2][3][4][5]. In diseases, altered NRIP1 expression and activity is implicated in a variety of cancers—where it can serve both tumor-promoting and tumor-suppressive functions depending on context—metabolic syndrome, kidney development disorders, reproductive disorders, and cardiovascular disease[2][3][5]. While not presently a direct therapeutic target with approved drugs, its widespread involvement in nuclear receptor and metabolic signaling pathways makes NRIP1 a potential target for future drug discovery, albeit with significant safety considerations due to its global physiological regulatory functions[2][4][5].

Other names

RIP140Receptor-interacting protein 140Nuclear factor RIP140CAKUT3

Corepressive modulation of nuclear receptor activity, histone deacetylase recruitment, alteration of transcriptional activity (for any putative therapeutic targeting approaches)